PTD-DBM: what the research shows about hair growth and safety

Could PTD-DBM help with hair loss? The experimental peptide targets a signaling pathway involved in hair growth. In mouse experiments, treated skin grew hair and, after wounding, formed new hair follicles. Those findings give researchers a reason to investigate the approach. They do not yet establish an effective or safe treatment for people.

PTD-DBM has no FDA-approved medical use. This article explains the science and its limits; it does not provide a treatment protocol or replace a medical assessment of hair loss.

The research and regulatory context below was checked in October 2026. The legal discussion concerns the United States; rules in Germany and other countries may differ.

Key points

• PTD-DBM is not an FDA-approved medicine. It is absent from the FDA’s reviewed May 14, 2026 list of bulk substances nominated for compounding under section 503A. That list is not a registry of every investigational medicine. A missing public application record cannot establish that no confidential development program exists.
• The direct treatment evidence is preclinical, chiefly mouse experiments and laboratory studies of cells involved in hair growth. Human scalp tissue observations help explain the proposed target, but they are not trials showing that treating a person with PTD-DBM regrows hair.
• CosmeRNA should not be confused with PTD-DBM. The published research behind CosmeRNA’s AR68 approach concerns an RNA-based androgen-receptor target, not this CXXC5-binding peptide. A product’s commercial availability is not evidence for a different compound.
• PTD-DBM combines a protein transduction domain with a Dishevelled-binding motif. It is designed to interrupt the interaction between CXXC5 and Dishevelled, allowing stronger Wnt/β-catenin signaling.
• Hair regrowth and the formation of new follicles have been observed in mouse models. No completed, peer-reviewed human efficacy trial was identified in the literature checked for this article. The appropriate human dose, formulation and treatment duration remain unknown.
• Database identifiers such as a PubChem CID describe chemical identity, not clinical validation or approval. The central starting point for the hair-growth hypothesis is the 2017 PTD-DBM mouse study in the Journal of Investigative Dermatology.

Where PTD-DBM came from and how it is intended to work

Origins and discovery

PTD-DBM grew out of research in Kang-Yell Choi’s laboratory at Yonsei University in South Korea. A 2015 paper by Kim and colleagues in Cell Death and Differentiation identified CXXC5 as a negative-feedback regulator of the Wnt/β-catenin pathway. In other words, CXXC5 helps turn down a signaling system after it has been activated.

The researchers found that CXXC5 binds directly to Dishevelled, usually abbreviated Dvl. This scaffold protein helps transmit canonical Wnt signals, the branch of Wnt signaling involving β-catenin. Binding by CXXC5 suppresses downstream activity.

A second 2015 study, in the Journal of Experimental Medicine, extended that finding to skin repair. Interrupting the CXXC5–Dvl interaction accelerated wound healing in mice. Together, the findings suggested that blocking the same interaction might also affect hair follicles.

The resulting peptide was described in the 2017 hair-growth paper. Its name reflects its two parts. PTD means protein transduction domain, a sequence intended to help a molecule enter cells. DBM means Dishevelled-binding motif. This portion competes with CXXC5 for a binding region on Dvl called its PDZ domain.

Cell entry and passage through intact human skin are separate problems. Including a PTD may help a peptide reach an intracellular target under experimental conditions; it does not establish that a scalp preparation will cross the human skin barrier in a predictable, useful amount.

Wnt/β-catenin signaling and the hair cycle

Wnt/β-catenin signaling helps control follicle development, regeneration and the repeating hair-growth cycle. When Wnt molecules activate their receptors, β-catenin can accumulate and enter the cell nucleus. There it influences genes involved in moving follicles into anagen, the active growth phase.

A broad 2022 review by Liu and colleagues in Signal Transduction and Targeted Therapy describes the pathway’s biological roles across different tissues. These include folliculogenesis, the formation of hair follicles. Wnt is therefore a plausible research target, although its importance in several organs also makes careful control relevant to safety.

Under particular experimental conditions, Wnt activity can help adult skin form entirely new follicles after an injury. Researchers call this wound-induced hair neogenesis, or WIHN. A foundational 2007 Nature study by Ito, Cotsarelis and colleagues demonstrated this in adult mouse skin. The finding involved new follicles, not simply the reactivation of follicles already present.

That possibility makes Wnt-based approaches especially interesting: conventional hair-loss treatments primarily act on existing follicles. A 2020 review by Wier and Garza in Seminars in Cell and Developmental Biology explores these regenerative signals after wounding. Whether a similar process can be harnessed safely to treat human pattern hair loss remains an unanswered clinical question.

Releasing the CXXC5 brake

CXXC5 participates in a feedback loop. As Wnt activity rises, cells produce more CXXC5, which binds Dvl and reduces further signaling. This is one way the pathway regulates its own activity.

PTD-DBM is designed to interrupt the loop by competing for the same binding site. Its DBM component occupies a pocket in the Dvl PDZ domain that CXXC5 uses to suppress signaling. A 2017 structural study by Lee, Choi and colleagues in Biochemical and Biophysical Research Communications determined the crystal structure of the mouse Dvl-1 PDZ domain and used molecular modeling to characterize its interaction with CXXC5.

Displacing CXXC5 removes one inhibitory influence on Wnt/β-catenin signaling. The concept is to release a biological brake. It would be a mistake, however, to assume that removing a natural brake necessarily produces a safely bounded response. The mechanism alone cannot rule out excessive signaling or effects in an unintended tissue.

A 2017 commentary by Kim and Garza in the Journal of Investigative Dermatology discussed CXXC5 inhibition as a new route to Wnt activation. Earlier approaches had acted through Wnt ligands or receptor complexes further upstream.

For a topical treatment, the other challenge is delivery. A compound has to cross the stratum corneum, the skin’s outer barrier, and reach the cells in which the relevant interaction occurs. Cells of the dermal papilla at the follicle’s base help regulate hair growth. Protein transduction domains can assist transport across cell membranes, but successful delivery to these cells in a human scalp still needs to be demonstrated for the proposed formulation. Neither reliable local exposure nor the extent of absorption elsewhere in the body has been established clinically.

CXXC5, DHT and androgenetic alopecia

A 2023 Cells paper by Ryu, Park and colleagues examined how CXXC5 fits into androgenetic alopecia, or AGA, the common hereditary, hormone-influenced pattern of hair loss.

The study linked dihydrotestosterone, or DHT, and prostaglandin D2, or PGD2, to increased CXXC5 activity and suppression of Wnt signaling. Its experiments included mouse hair-growth and wound-induced follicle models, as well as cellular work. Blocking CXXC5, including with PTD-DBM, countered PGD2-related suppression in those models. Inhibiting both CXXC5 and GSK3β also alleviated DHT-induced hair-growth inhibition experimentally.

The proposed chain is DHT and PGD2 signaling, increased CXXC5-mediated inhibition, and reduced Wnt activity that interferes with the hair cycle. That gives the approach a more specific biological rationale than a nonspecific claim to stimulate hair.

These remain preclinical findings. Human tissue observations can identify a potentially relevant target, but they cannot show that interrupting it produces meaningful regrowth in a person with AGA. That step requires treatment studies in people.

What the preclinical studies show

The foundational 2017 mouse study

The central PTD-DBM hair-growth experiment was the 2017 study by Lee, Seo, Pi and colleagues at Yonsei University. Researchers applied the peptide to the back skin of C57BL/6N mice and assessed hair regrowth and the formation of new follicles after wounding.

Treated mice showed visible regrowth, and the WIHN experiments produced new follicles. Combining PTD-DBM with valproic acid, or VPA, had stronger effects than either compound alone. VPA inhibits GSK3β, an enzyme involved in Wnt regulation, and can activate the pathway through a different mechanism.

The study also investigated molecular changes. Protein-binding experiments, including pull-down assays, examined disruption of the CXXC5–Dvl interaction. The observations included increased nuclear β-catenin and greater expression of downstream Wnt target genes. These measurements connected the visible hair response with the proposed biological pathway.

The results provide experimental support for the target and the competing-peptide approach. Their relevance to treatment still has limits. Mouse follicles and wounded mouse skin differ from the slowly progressive, multifactorial process of human pattern hair loss. The cited PTD-DBM literature is concentrated in one research program; stronger evidence would include independent replication as well as human trials. A short animal experiment cannot answer questions about years of scalp use, durability of regrowth or uncommon adverse effects.

Valproic acid and research on delivery

Valproic acid had already been studied as a Wnt activator before the PTD-DBM hair experiments. A 2012 PLOS ONE study by Lee, Yoon and colleagues reported hair regeneration in C57BL/6 mice and increased alkaline phosphatase activity in cultured human dermal papilla cells.

There is also a small human VPA trial, which must be kept separate from evidence for PTD-DBM. A 2014 randomized, double-blind, placebo-controlled feasibility study by Jo, Shin and colleagues enrolled 40 men with moderate AGA. Twenty-seven completed the 24-week protocol with good adherence: 15 used 8.3% sodium valproate spray and 12 used placebo.

Hair count was assessed photographically with a phototrichogram. The mean change favored VPA, with p = 0.047. Most reported adverse events were mild and self-limited; their frequency did not differ significantly between groups, with p = 0.72. One participant using VPA developed ventricular tachycardia, which the investigators did not consider apparently related to the spray. This event and the small number of completers matter when interpreting safety.

A statistically significant hair-count result in a small feasibility trial is not a measure of how noticeable a benefit will be for an individual. Nor does a nonsignificant difference in adverse-event rates establish equivalent safety. Most importantly, the trial tested VPA alone, not PTD-DBM or their combination.

A 2023 Advanced Healthcare Materials study by Lee, An, Ryu and colleagues investigated an adhesive hydrogel patch combining PTD-DBM and VPA. It promoted regenerative wound repair with reduced scarring in preclinical models. This extends the biological question beyond hair growth to skin repair, but does not supply human safety or efficacy data for a scalp treatment.

The skin barrier remains important for both agents. A 2018 Biomaterials paper by Lahiji and colleagues tested dissolving microneedles carrying VPA and observed regrowth in mice. That work illustrates why delivery systems matter. It does not validate PTD-DBM’s penetration through human skin or establish a therapeutic concentration for people.

Related compounds from the Choi laboratory

The Yonsei research program has also studied small molecules acting on the same biology. A 2021 British Journal of Pharmacology paper by Ryu, Lee and colleagues investigated KY19382, an indirubin-3′-monoxime derivative that activates Wnt/β-catenin signaling.

KY19382 promoted hair regrowth, follicle formation and hair-shaft elongation in experimental systems. These included C57BL/6N mice, follicle-neogenesis experiments in hairless mice, and human hair follicles maintained outside the body. Topical 0.5 mM KY19382 was compared with 100 µM minoxidil; 5 µM KY19382 was used in dermal papilla cell experiments. For clarity, 0.5 mM equals 500 µM. These are experimental concentrations, not equivalent clinical doses. Several reported comparisons for key outcomes had p values below 0.05.

PTD-DBM and KY19382 represent different chemical approaches to CXXC5-related signaling. KY19382 also affects GSK3β, so its results cannot simply be assigned to the peptide. Cultured human follicles are useful for studying human biology, but they are not the same as administering a treatment to patients. Neither compound has established clinical efficacy for human hair loss in the evidence reviewed here.

A related 2023 Experimental and Molecular Medicine study by Kim, Seo and colleagues found that inhibiting the cytosolic function of CXXC5 accelerated diabetic wound repair in preclinical models, with greater angiogenesis and skin repair. Angiogenesis means the formation of new blood vessels.

Together, these studies make CXXC5 a credible biological target for further research. Target validation and clinical validation are different milestones: demonstrating that a pathway matters does not yet establish which drug, formulation or dose will help patients safely.

Evidence in people: what exists and what is missing

Human clinical evidence through October 2026

The literature checked for this article did not identify a completed, peer-reviewed human trial demonstrating PTD-DBM’s effectiveness for AGA or another indication. The direct evidence discussed above comes from laboratory and animal work. No claim of a comprehensive audit of confidential development programs is possible from public searches.

Human cells, removed scalp tissue and isolated follicles can make an experimental finding more relevant to human biology. They do not tell us whether a scalp product improves a patient’s hair density, how long an effect lasts, or what adverse events occur with repeated use.

CosmeRNA does not fill this evidence gap. Its published SAMiRNA/AR68 research concerns RNA targeting the androgen receptor. It is a different intervention from PTD-DBM, and its studies cannot be used as PTD-DBM clinical trials. The names CosmeRNA and Epi Biotech should not be treated as interchangeable products or companies.

Commercial availability alone establishes neither clinical benefit nor safety. A 2021 review by Ji, Zhu, Sun and Fu in Signal Transduction and Targeted Therapy examines tissue engineering, signaling and the translation of functional follicle regeneration into practice. Wnt-targeted regeneration is an active research area, with substantial work still separating promising models from validated treatments.

How PTD-DBM compares with established AGA treatments

Minoxidil and finasteride provide useful reference points because they have human treatment data. A 2017 systematic review and meta-analysis by Adil and Godwin in the Journal of the American Academy of Dermatology pooled randomized trials of oral finasteride 1 mg, topical minoxidil at 2% and 5%, and low-level laser therapy.

The five pooled comparisons favored the respective treatments over placebo, with p < 0.00001. The review considered outcomes including hair density, thickness, the balance of anagen to telogen hairs, and global assessment. The anagen-to-telogen ratio compares hairs in active growth with those in the resting phase. The size and relevance of the benefit still depend on the treatment and outcome; a small p value alone does not convey either.

A 2022 network meta-analysis by Gupta, Venkataraman and colleagues in JAMA Dermatology included 23 studies. Regimens included oral minoxidil at 0.25 and 5 mg daily, topical minoxidil at 2% and 5%, finasteride at 1 and 5 mg daily, and dutasteride at 0.5 mg daily, among others. Reported study mean ages ranged from 22.8 to 41.8 years; this was not the youngest-to-oldest range of individual participants.

The analysis compared hair counts after 24 and 48 weeks. Dutasteride 0.5 mg daily ranked highest for total hair-count improvement at 24 weeks. At 48 weeks, finasteride 5 mg and 1 mg daily outperformed 2% topical minoxidil for the reported total hair-count comparisons. A network analysis combines direct and indirect comparisons, so its rankings depend on the available studies and their quality. It is not a single head-to-head trial of all the drugs.

Minoxidil has effects involving potassium channels and vascular biology, although its hair-growth mechanism is not completely resolved. A 1990 study by Buhl and colleagues identified minoxidil sulfate as an active metabolite that stimulates follicles. That finding does not demonstrate that every part of its mechanism is independent of Wnt. Finasteride inhibits 5-α-reductase and reduces DHT.

PTD-DBM is intended to act at a different point, by interrupting CXXC5-mediated suppression of Wnt signaling. That distinction is scientifically interesting; it does not establish superiority, an additive benefit, or a reason to replace a treatment supported by clinical trials.

Certain minoxidil and finasteride formulations and indications have FDA approval. PTD-DBM does not. Listing a dose included in a meta-analysis is not a recommendation to use it, and not every listed dose, drug or route is approved for AGA.

Regulatory and legal status

FDA status and investigational development

PTD-DBM has no FDA-approved human indication. It was not listed in the FDA’s May 14, 2026 document of bulk substances nominated under section 503A, the US framework relevant to certain pharmacy-compounded preparations. Inclusion in a nomination category would itself be different from approval of a finished medicine.

An important distinction concerns investigational new drug applications, or INDs, and new drug applications, or NDAs. Public searches cannot establish that no application has ever been filed. Under 21 CFR 312.130, the FDA generally does not disclose an IND’s existence unless it has already been publicly disclosed or acknowledged. A missing DailyMed entry is likewise not a complete account of investigational development.

The practical conclusion is narrower and clearer: an FDA-approved PTD-DBM treatment, prescribing label and established routine-care formulation are not available. Publicly accessible preclinical papers are not a substitute for the authorization and evidence required for clinical use.

What this means in practice

An online product labeled PTD-DBM should not be assumed to have undergone FDA evaluation of identity, purity, potency, safety or effectiveness. Without reliable manufacturing and analytical information, the contents and concentration of a research product may be uncertain.

The legal status of a particular purchase or supply arrangement depends on the product, intended use, jurisdiction and applicable rules. It is too broad to infer from a missing database entry that every conceivable possession or research use is unlawful. Conversely, a seller’s willingness to ship a product does not establish that it can lawfully be supplied as a treatment.

Cosmetic marketing also differs from drug approval. Claims about CosmeRNA cannot establish a legitimate PTD-DBM supply route because the interventions are different. A clinician’s involvement or a prescription alone does not turn an unapproved research product into an FDA-approved medicine.

These regulatory distinctions describe the conditions for clinical development and use. They do not decide whether the underlying biological hypothesis deserves further investigation.

PTD-DBM, GHK-Cu and other topical peptides

PTD-DBM is sometimes discussed alongside skin and hair peptides such as GHK-Cu. The shared label “peptide” can obscure important differences in chemistry and biological targets.

GHK-Cu is a copper-binding tripeptide, made from three amino acids. Research discussions commonly focus on extracellular matrix remodeling, inflammatory processes and collagen synthesis. The extracellular matrix is the supporting material around cells. In hair-related research, proposed effects include maintenance of the follicular environment and its blood supply.

PTD-DBM is designed to enter cells and interfere specifically with CXXC5 binding to Dvl. Its proposed effects concern Wnt-mediated regulation of the hair cycle and, in experimental wound models, the formation of new follicles. This is different from supporting the surrounding matrix.

These mechanistic differences do not establish a clinical ranking. The cited material does not provide a specific controlled human GHK-Cu hair-loss trial that would support a direct comparison with PTD-DBM. Cosmetic or dermatologic findings for one formulation also cannot automatically be transferred to a different peptide or to AGA. Neither comparison supplies the missing human PTD-DBM safety and efficacy data, and neither justifies treating the two peptides as interchangeable substitutes for established care.

Safety: what is known and what is not

Missing clinical safety data

No published phase 1 human PTD-DBM safety dataset was identified in the research reviewed here. Early clinical studies usually help establish tolerability, exposure and other basic properties before larger efficacy trials are considered.

Consequently, the human safety profile remains unknown. Open questions include local irritation, allergic or other immune reactions, absorption after scalp application, and effects in tissues beyond the intended treatment area. Immunogenicity means a substance’s ability to trigger an immune response.

The mouse hair-growth papers do not establish a comprehensive human safety profile. Failure to report an obvious adverse effect in a particular animal experiment is not the same as systematic toxicology testing. A study designed to measure hair regrowth may be too short or too small to detect a different type of harm.

The PTD component is intended to facilitate cell entry. Whether a topical human formulation would remain largely local or create appreciable systemic exposure has not been established. Neither harmless confinement to the scalp nor extensive absorption should be assumed from the peptide’s design alone.

Theoretical concerns arising from the mechanism

Wnt/β-catenin signaling influences cell proliferation and tissue growth. Abnormally active Wnt signaling is involved in several cancers. That creates a theoretical concern that a drug increasing this activity could favor unwanted growth in a susceptible setting.

Interrupting CXXC5–Dvl is a more targeted intervention than directly adding Wnt ligands, but targeting a regulatory interaction does not automatically make it safe. Removing an inhibitory influence can still alter the behavior of cells beyond the intended outcome.

The oncologic consequences of repeated local Wnt activation by PTD-DBM have not been established in people. The concern here is derived from pathway biology, not a demonstrated PTD-DBM cancer outcome in patients. Keeping that distinction matters: it is a reason for appropriate safety research, not proof that the peptide causes cancer.

Risks from poorly controlled sources

Research-product quality is a separate issue from the molecule’s pharmacology. An online listing may provide little dependable information about production, independent identity testing, purity or consistency between batches. Each product needs its own credible documentation.

Potential problems include incorrect concentrations, misidentified material and contamination. Heavy metals and bacterial endotoxins are examples of contaminants relevant to pharmaceutical quality; endotoxins can trigger strong inflammatory responses. These possibilities should not be presented as laboratory-confirmed findings about every PTD-DBM product. The references here do not include a market-wide analytical survey establishing their frequency.

Even a correctly identified, high-purity research compound would still lack established human dosing and clinical safety data. Product testing and clinical evaluation answer different questions.

Who should avoid PTD-DBM?

PTD-DBM is not supported for routine self-treatment. Any human investigation would need appropriate ethics review and the applicable regulatory authorization, not merely a claim that a study has an institutional review board’s approval. No patient group has a clinically established indication for the peptide.

Some circumstances raise particular theoretical concerns. These are not a validated contraindication table for an approved drug:

• A current or previous cancer warrants particular caution because Wnt participates in growth regulation and cancer biology. This includes concerns about skin and follicular tissues, although different cancers have different dominant pathways. A specific PTD-DBM risk has not been measured.
• A personal or family history of a syndrome involving abnormal Wnt regulation, such as APC-related familial adenomatous polyposis, makes the mechanism especially relevant to discuss with specialists.
• During pregnancy or breastfeeding, human reproductive and developmental safety data are lacking. Wnt signaling is central to embryonic development and tissue organization.
• A history of hypersensitivity to a peptide or protein formulation does not predict PTD-DBM tolerance with confidence. Human allergy data are missing.
• Athletes subject to anti-doping rules should treat an unapproved pharmacologic research substance as a serious eligibility concern. The 2026 WADA list’s S0 category covers substances without governmental approval for human therapeutic use that are not addressed by another category, and prohibits them at all times. Absence of the name PTD-DBM from a list of examples is not permission to use it; athletes should obtain a substance-specific determination from their anti-doping organization.

When to seek an assessment for hair loss

Hair loss is common, and more than one cause can be present. Pattern hair loss, diffuse shedding and inflammatory scalp conditions do not necessarily need the same evaluation or treatment. A clinician can examine the pattern, timing, scalp findings, medicines and relevant medical history before deciding what to investigate.

Targeted blood tests may help when the history or examination suggests a thyroid problem, iron deficiency or another contributing condition. A broad hormone and inflammation panel is not automatically the best first step for every person with thinning hair. In particular, routine blood DHT testing is not required to explain every case of AGA.

Finding and treating a genuine deficiency or underlying illness can be useful. It does not follow that deficiency correction will outperform established treatment for every type of hair loss. A nutrient supplement cannot be expected to correct a mechanism unrelated to a deficiency.

PTD-DBM offers a biologically coherent research hypothesis. For a treatment decision, however, what matters is whether a particular intervention produces worthwhile benefits at acceptable risk in people. A compelling cellular mechanism cannot answer that question on its own.

Important safety information

PTD-DBM is not FDA-approved for any medical use. The research discussed here is predominantly laboratory and animal work; no completed human efficacy trial was identified. Human safety, effective dosing, treatment duration and long-term outcomes remain undetermined.

The full adverse-effect profile, immune effects and extent of systemic absorption are unknown. There is no approved prescribing label or clinically validated contraindication table. Cancer-related pathway biology and the importance of Wnt in development create particular theoretical concerns during pregnancy, breastfeeding and in susceptible medical circumstances.

Any investigational human use requires appropriate regulatory and ethics oversight. A cell-penetrating sequence does not establish reliable scalp delivery, beneficial exposure or freedom from effects elsewhere in the body.

For online products, trustworthy identity and quality information may also be missing. Possible manufacturing or labeling problems must be distinguished from documented findings about a particular batch. Even sound manufacturing would not resolve the absent clinical evidence.

Questions about the cause of hair loss and evidence-based options belong in a dermatologic or other qualified medical assessment. This article is educational and does not provide instructions for preparing or using PTD-DBM.

Frequently asked questions

Is PTD-DBM FDA-approved?

No. PTD-DBM does not have an FDA-approved medical indication or an approved prescribing label. It was also absent from the May 14, 2026 nomination document discussed above.

Drug approval, compounding eligibility and permission to conduct an investigational study are different regulatory questions. A missing public IND or NDA record cannot prove that no confidential application exists. None of these distinctions supplies an established approved PTD-DBM treatment for routine care.

Is PTD-DBM legal in the United States?

It is not an FDA-approved treatment. A lawful route for routine therapeutic supply cannot be assumed from an online research listing.

Whether a specific purchase, possession, import or research use is lawful depends on the facts and applicable rules. “Research use only” is not a general authorization to administer a product to people. Equally, a missing public database entry is not enough to make a blanket legal statement about every possible use.

Can a doctor prescribe PTD-DBM?

There is no established FDA-approved PTD-DBM product to prescribe. PTD-DBM was not listed in the FDA’s May 14, 2026 bulk-substance nomination document, including its category 1 section.

A prescription by itself does not establish that a pharmacy may lawfully compound or supply a substance. Compounding has specific statutory and policy requirements, and nominated substances are not equivalent to approved drugs. A clinician or pharmacy would need to establish the applicable legal basis rather than infer eligibility from a product listing.

Does PTD-DBM work for hair loss in people?

That has not been established. The reviewed literature did not identify a completed human trial demonstrating regrowth in AGA or another type of hair loss.

Mouse experiments and laboratory findings support a plausible biological mechanism. They justify investigation, while leaving the clinical questions open: whether it helps, by how much, for whom, for how long and at what risk.

How does PTD-DBM differ from finasteride and minoxidil?

Finasteride reduces DHT by inhibiting 5-α-reductase. Minoxidil has effects involving potassium channels and other follicular processes. PTD-DBM is intended to disrupt the CXXC5–Dvl interaction and release inhibition of Wnt/β-catenin signaling.

Finasteride and minoxidil have approved uses and substantial human trial evidence, although not every formulation or dose is approved for hair loss. Comparable human treatment evidence is missing for PTD-DBM. A different target does not itself demonstrate an advantage over either drug.

What is Wnt signaling, and why does it matter for hair?

Wnt/β-catenin signaling helps regulate the transition into anagen, the active growth phase. In adult mouse skin, activating the pathway after wounding can also contribute to the formation of entirely new follicles. The same therapeutic result in humans has not been demonstrated by these animal experiments.

CXXC5 helps limit Wnt activity through negative feedback. Experimental work links DHT and PGD2 to this inhibitory mechanism. PTD-DBM is designed to interrupt it. This is an interesting approach to follicle biology, but controlling the strength, location and duration of Wnt activity remains part of the research challenge.

Is CosmeRNA or Epi Biotech the same as PTD-DBM, and is it safe?

CosmeRNA is not PTD-DBM. The published CosmeRNA-related SAMiRNA/AR68 work concerns RNA targeting the androgen receptor, not a peptide interrupting CXXC5–Dvl binding. CosmeRNA and Epi Biotech should not be treated as interchangeable names.

Evidence about a named cosmetic formulation applies to that formulation and its studied conditions. It cannot establish the safety or effectiveness of PTD-DBM. Commercial availability and cosmetic status also differ from approval as a medicine. The human safety questions for PTD-DBM remain unresolved.

Have peptides become legal again in 2026?

There is no single regulatory status covering all peptides. Some are approved medicines, while others are investigational or marketed as research substances. Changes to one compounding list do not authorize the whole category.

The FDA page on bulk substances that may present significant safety risks separates current category 2 substances from substances whose nominations were withdrawn. Removal following withdrawal is not drug approval or a blanket finding of safety.

PTD-DBM is not named in the reviewed May 14, 2026 nomination document. That observation should not be expanded into an unverified claim about every historical version of every list. It does not change the central point: PTD-DBM has no FDA-approved indication and no established human treatment evidence in the literature reviewed here.

This article is for education. PTD-DBM is not an FDA-approved treatment, and the information here does not replace medical advice, diagnosis or care.

References and sources

1. Lee SH, Seo SH, Lee DH, Pi LQ, Lee WS, Choi KY (2017). Targeting of CXXC5 by a Competing Peptide Stimulates Hair Regrowth and Wound-Induced Hair Neogenesis. The Journal of investigative dermatology, 137(11), 2260-2269. https://doi.org/10.1016/j.jid.2017.04.038. PubMed

2. Kim HY, Yoon JY, Yun JH, Cho KW, Lee SH, Rhee YM, Jung HS, Lim HJ, Lee H, Choi J, Heo JN, Lee W, No KT, Min D, Choi KY (2015). CXXC5 is a negative-feedback regulator of the Wnt/β-catenin pathway involved in osteoblast differentiation. Cell death and differentiation, 22(6), 912-20. https://doi.org/10.1038/cdd.2014.238. PubMed

3. Lee SH, Kim MY, Kim HY, Lee YM, Kim H, Nam KA, Roh MR, Min, d. o. S., Chung KY, Choi KY (2015). The Dishevelled-binding protein CXXC5 negatively regulates cutaneous wound healing. The Journal of experimental medicine, 212(7), 1061-80. https://doi.org/10.1084/jem.20141601. PubMed

4. Liu J, Xiao Q, Xiao J, Niu C, Li Y, Zhang X, Zhou Z, Shu G, Yin G (2022). Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities. Signal transduction and targeted therapy, 7(1), 3. https://doi.org/10.1038/s41392-021-00762-6. PubMed

5. Ito M, Yang Z, Andl T, Cui C, Kim N, Millar SE, Cotsarelis G (2007). Wnt-dependent de novo hair follicle regeneration in adult mouse skin after wounding. Nature, 447(7142), 316-20. https://doi.org/10.1038/nature05766. PubMed

6. Wier EM, Garza LA (2020). Through the lens of hair follicle neogenesis, a new focus on mechanisms of skin regeneration after wounding. Seminars in cell & developmental biology, 100, 122-129. https://doi.org/10.1016/j.semcdb.2019.10.002. PubMed

7. Lee I, Choi S, Yun JH, Seo SH, Choi S, Choi KY, Lee W (2017). Crystal structure of the PDZ domain of mouse Dishevelled 1 and its interaction with CXXC5. Biochemical and biophysical research communications, 485(3), 584-590. https://doi.org/10.1016/j.bbrc.2016.12.023. PubMed

8. Kim D, Garza LA (2017). The Negative Regulator CXXC5: Making WNT Look a Little Less Dishevelled. The Journal of investigative dermatology, 137(11), 2248-2250. https://doi.org/10.1016/j.jid.2017.07.826. PubMed

9. Ryu YC, Park J, Kim YR, Choi S, Kim GU, Kim E, Hwang Y, Kim H, Han G, Lee SH, Choi KY (2023). CXXC5 Mediates DHT-Induced Androgenetic Alopecia via PGD2. Cells, 12(4). https://doi.org/10.3390/cells12040555. PubMed

10. Lee SH, Yoon J, Shin SH, Zahoor M, Kim HJ, Park PJ, Park WS, Min, d. o. S., Kim HY, Choi KY (2012). Valproic acid induces hair regeneration in murine model and activates alkaline phosphatase activity in human dermal papilla cells. PloS one, 7(4), e34152. https://doi.org/10.1371/journal.pone.0034152. PubMed

11. Jo SJ, Shin H, Park YW, Paik SH, Park WS, Jeong YS, Shin HJ, Kwon O (2014). Topical valproic acid increases the hair count in male patients with androgenetic alopecia: a randomized, comparative, clinical feasibility study using phototrichogram analysis. The Journal of dermatology, 41(4), 285-91. https://doi.org/10.1111/1346-8138.12422. PubMed

12. Lee SH, An S, Ryu YC, Seo SH, Park S, Lee MJ, Cho SW, Choi KY (2023). Adhesive Hydrogel Patch-Mediated Combination Drug Therapy Induces Regenerative Wound Healing through Reconstruction of Regenerative Microenvironment. Advanced healthcare materials, 12(18), e2203094. https://doi.org/10.1002/adhm.202203094. PubMed

13. Fakhraei Lahiji S, Seo SH, Kim S, Dangol M, Shim J, Li CG, Ma Y, Lee C, Kang G, Yang H, Choi KY, Jung H (2018). Transcutaneous implantation of valproic acid-encapsulated dissolving microneedles induces hair regrowth. Biomaterials, 167, 69-79. https://doi.org/10.1016/j.biomaterials.2018.03.019. PubMed

14. Ryu YC, Lee DH, Shim J, Park J, Kim YR, Choi S, Bak SS, Sung YK, Lee SH, Choi KY (2021). KY19382, a novel activator of Wnt/β-catenin signalling, promotes hair regrowth and hair follicle neogenesis. British journal of pharmacology, 178(12), 2533-2546. https://doi.org/10.1111/bph.15438. PubMed

15. Kim E, Seo SH, Hwang Y, Ryu YC, Kim H, Lee KM, Lee JW, Park KH, Choi KY (2023). Inhibiting the cytosolic function of CXXC5 accelerates diabetic wound healing by enhancing angiogenesis and skin repair. Experimental & molecular medicine, 55(8), 1770-1782. https://doi.org/10.1038/s12276-023-01064-3. PubMed

16. Ji S, Zhu Z, Sun X, Fu X (2021). Functional hair follicle regeneration: an updated review. Signal transduction and targeted therapy, 6(1), 66. https://doi.org/10.1038/s41392-020-00441-y. PubMed

17. Adil A, Godwin M (2017). The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis. Journal of the American Academy of Dermatology, 77(1), 136-141.e5. https://doi.org/10.1016/j.jaad.2017.02.054. PubMed

18. Gupta AK, Venkataraman M, Talukder M, Bamimore MA (2022). Relative Efficacy of Minoxidil and the 5-α Reductase Inhibitors in Androgenetic Alopecia Treatment of Male Patients: A Network Meta-analysis. JAMA dermatology, 158(3), 266-274. https://doi.org/10.1001/jamadermatol.2021.5743. PubMed

19. Buhl AE, Waldon DJ, Baker CA, Johnson GA (1990). Minoxidil sulfate is the active metabolite that stimulates hair follicles. The Journal of investigative dermatology, 95(5), 553-7. https://doi.org/10.1111/1523-1747.ep12504905. PubMed

20. U.S. Food and Drug Administration. (2026). Certain bulk drug substances for use in compounding that may present significant safety risks. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks

21. U.S. Food and Drug Administration. (2026). Bulk drug substances nominated for use in compounding under section 503A of the Federal Food, Drug, and Cosmetic Act (updated May 14, 2026). https://www.fda.gov/media/94155/download

22. Additional background article on hair-growth supplements, not a primary clinical trial: https://superpower.com/supplement-guides/do-hair-growth-supplements-work

23. Weekly treatment with SAMiRNA targeting the androgen receptor ameliorates androgenetic alopecia. Scientific Reports (2022). https://www.nature.com/articles/s41598-022-05544-w

24. 21 CFR 312.130. Availability for public disclosure of data and information in an IND. https://www.ecfr.gov/current/title-21/section-312.130

25. World Anti-Doping Agency. The 2026 Prohibited List. https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf?embed=true